
CLEARPOINT NEURO INC
CLPTNASDAQTrading Snapshot
- Day Range
- $14.50 β $14.79
- 52-Week Range
- $8.27 β $30.10
- Volume
- $3.54B
- Avg Volume
- $2.36B
- Shares Outstanding
- 30.0M
- Next Earnings
- Oct 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $37M
- Last Q Revenue
- $11M
- P/E Ratio
- β
- P/S Ratio
- 11.0x
- EPS (TTM)
- $-1.01
- Dividend Yield
- β
Why Investors Own CLPT
- βHigh-growth profile β revenue up +39.6% YoY with expanding US Equity exposure.
- βHealthy economics β 56% gross margin and 21% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CLEARPOINT NEURO INC
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates

ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case
ClearPoint Neuro's Q2 miss and preclinical delays weigh on 2026, but regulatory clarity boosts 2027-28 upside. Click to see risks, dilution and outlook.

12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular session. The company's market cap stands at $1.9 million. Adagio Medical Holdings (NASDAQ:ADGM) shares increased by

Crude Oil Down Over 5%; McDonald's Earnings Top Views
U.S. stocks gain with Nasdaq up more than 2% on Tuesday. Dow up 1.79% to 54,129.35, Nasdaq up 2.22% to 26,490.24, S&P 500 up 1.64% to 7,725.48. Tech shares jump 3.8%, utilities down 0.5%. McDonald's beats earnings estimates. Ibotta, Backblaze, Corvex up, Adapthealth, Better Home & Finance, Clearpoint Neuro down.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings (NASDAQ:ADGM) stock

Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks Moving Lower In Tuesdayβs Pre-Market Session
U.S. stock futures rise on Tuesday, but Powell Industries Inc shares fall 13.4% after reporting lower-than-expected earnings and sales.

Why Palantir Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving Premarket
Palantir Technologies Inc (PLTR) shares jumped 16.1% in pre-market trading on upbeat Q2 results, with revenue of $1.94B and EPS of 41 cents. Other gainers include RAIN, ENSC, ELPW, DXST, ADGM, AMRC, BLZE, VOYG, LIFE. Losers include RITR and HYFM.